Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Zalutsky

Showing results (1-10 of 149) with videos related to

Pageof 15
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Current status of therapy of solid tumors: brain tumor therapyMichael R Zalutsky
Current Radiopharmaceuticals|December 29, 2011
Astatine-211: production and availabilityMichael R Zalutsky, Marek Pruszynski
Nuclear Medicine and Biology|June 18, 2021
Production, purification and availability of <sup>211</sup>At: Near term steps towards global accessYutian Feng, Michael R Zalutsky
Nature Protocols|April 5, 2007
Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptidesGanesan Vaidyanathan, Michael R Zalutsky
Current Radiopharmaceuticals|February 13, 2010
Astatine Radiopharmaceuticals: Prospects and ProblemsGanesan Vaidyanathan, Michael R Zalutsky
Current Radiopharmaceuticals|December 29, 2011
Applications of 211At and 223Ra in targeted alpha-particle radiotherapyGanesan Vaidyanathan, Michael R Zalutsky
Nature Protocols|April 5, 2007
Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteinsGanesan Vaidyanathan, Michael R Zalutsky
Nature Protocols|May 10, 2007
Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18FGanesan Vaidyanathan, Michael R Zalutsky
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particlesOscar R Pozzi, Michael R Zalutsky
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 9, 2005
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesisOscar R Pozzi, Michael R Zalutsky
Pageof 15

Showing results (1-10 of 149) with videos related to

Sort By:
Pageof 15
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Current status of therapy of solid tumors: brain tumor therapyMichael R Zalutsky
Current Radiopharmaceuticals|December 29, 2011
Astatine-211: production and availabilityMichael R Zalutsky, Marek Pruszynski
Nuclear Medicine and Biology|June 18, 2021
Production, purification and availability of <sup>211</sup>At: Near term steps towards global accessYutian Feng, Michael R Zalutsky
Nature Protocols|April 5, 2007
Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptidesGanesan Vaidyanathan, Michael R Zalutsky
Current Radiopharmaceuticals|February 13, 2010
Astatine Radiopharmaceuticals: Prospects and ProblemsGanesan Vaidyanathan, Michael R Zalutsky
Current Radiopharmaceuticals|December 29, 2011
Applications of 211At and 223Ra in targeted alpha-particle radiotherapyGanesan Vaidyanathan, Michael R Zalutsky
Nature Protocols|April 5, 2007
Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteinsGanesan Vaidyanathan, Michael R Zalutsky
Nature Protocols|May 10, 2007
Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18FGanesan Vaidyanathan, Michael R Zalutsky
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particlesOscar R Pozzi, Michael R Zalutsky
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 9, 2005
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesisOscar R Pozzi, Michael R Zalutsky
Pageof 15